International cooperation

Petrovax is open to cooperation and is interested in finding partners for joint work in the areas of R&D, production and launch of new products on the Russian and global markets.

our competitive advantages

  • original and in-demand portfolioOriginal and in-demand portfolio of innovative products; patents for new molecules and pharmaceutical manufacturing technologies in Russia and abroad
  • high-tech manufacturingHigh-tech biotechnological fill-cycle manufacturing  in accordance with the EAEU and EU GMP standards: from the synthesis of the APIs to the release of FDF
  • R&D investment programR&D investment program and conducting international multicenter clinical trials of original products
  • international experienceExperience in implementing international projects in the production and R&D fields in cooperation with Big Pharma companies: Pfizer, Abbott, Boehringer Ingelheim, ISU Abxis



a unique biopharmaceutical project in the scientific and industrial spheres

In cooperation with Abbott, a biopharmaceutical project to build a modern pharmaceutical complex for the development and production of immunobiological drugs in the Moscow region has been successfully implemented. In 2008, for the first time in Russia, the release of influenza vaccine Grippol® plus in disposable syringes without the preservative thiomersal was launched. It is one of the most exported influenza vaccines in Russia1 and is part of the state immunization programs of several countries.



the first project on import substitution of high-tech vaccines in Russia

In partnership with Pfizer, a project was implemented for the first time to introduce the technology for the full cycle of production of finished dosage forms, control and quality assurance of the 13-valent pneumococcal conjugate vaccine Prevenar® 13 in Russia. Since 2014, more than 35 million doses of the vaccine have been delivered to the Russian market, significant results in reducing mortality caused by pneumonia among children of the first year of life have been achieved — 56%2 reduction noted.

Boehringer Ingelheim


localization of biopharmaceutical drugs for the treatment of cardiovascular diseases

Throughout cooperation with the international company Boehringer Ingelheim, the local production of Actilyse® and Metalyse® drugs for the treatment of cardiovascular diseases were introduced to the acute phase of heart attacks and ischemic strokes treatment. The use of these drugs today is the "gold standard"3 of thrombolytic therapy. Petrovax is the second site in the world to produce innovative Boehringer Ingelheim thrombolytics.



technology transfer of the full cycle production of the drugs for the treatment of orphan disease, including substance synthesis

In cooperation with the South Korean company ISU Abxis, a project on localization of full-cycle production of agalsidase beta (Fabagal medicine) for the Fabry disease treatment is being implemented. Fabry is an orphan disease, which belongs to the group of lysosomal storage diseases and in the absence of timely diagnosis and therapy it leads to early disability and premature death of patients. As a result of the project, Petrovax will synthesize the substance and produce the finished dosage form.